7 completed. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 1 | Completed 1 |
Follow RSV Infection: new trials by email Literature Review of RSV Infection trials Research Report on RSV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 142 | 2023-11-20 | 2025-10-07 |
| A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV XW001, Placebo - RSV Infection | Phase 1 / Phase 2 | Completed | Hangzhou Sciwind Biosciences Co., Ltd. | 61 | 2023-04-20 | 2025-08-17 |
| A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. EDP-938, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 187 | 2022-11-29 | 2026-08-19 |
| Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults MVA-mBN294B, Placebo - RSV Infection | Phase 2 | Completed | Bavarian Nordic | 73 | 2021-02-22 | 2023-07-21 |
| Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine MV-012-968, Placebo - RSV Infection | Phase 2 | Completed | Meissa Vaccines, Inc. | 60 | 2020-12-29 | 2022-08-04 |
| Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children Nirsevimab - RSV Infection | Phase 2 | Completed | AstraZeneca | 100 | 2020-08-19 | 2023-11-15 |
| A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model EDP-938 Dose 1, EDP-938 Dose 2, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 179 | 2018-10-15 | 2022-05-03 |
Respiratory Syncytial Virus Infections (7)
Infections (7) · Mononegavirales Infections (7) · Paramyxoviridae Infections (7) · Pneumovirus Infections (7) · RNA Virus Infections (7) · Virus Diseases (7)
EDP-938 (1) · XW001 (1) · nirsevimab (1)
Enanta Pharmaceuticals, Inc (3) · AstraZeneca (1) · Bavarian Nordic (1) · Hangzhou Sciwind Biosciences Co., Ltd. (1) · Meissa Vaccines, Inc. (1)
United Kingdom (5) · Poland (2) · South Africa (2) · Spain (2) · United States (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · China (1) · Colombia (1) · Czechia (1) · Japan (1) · Malaysia (1) · Mexico (1) · Slovakia (1)
Hanmin Liu, Dr (1) · Mariya Kalinova, MD (1) · Oliver Medzihradsky, MD MPH MS (1) · Qin Yu (1)